I read arpemd's response to JPenis. If the regulatory obstacles described are accurate, I have to question why arpemd would even consider an investment in TOMDF. From the responses, it seems an almost impossible task to get approval for Tollovir/Tollovid given Todos' small size and limited resources.

Makes me wonder:

1. Does this person really know what they're talking about? If so, why invest in such an extreme long shot as described?

2. Is this person a plant to respond to JPenis in a manner that paints Todos efforts with Tollovir/Tollovid in an impossible scenario to gain approval?

JPenis is trying to sound knowledgeable, but he is in over his head. A few months ago he posted that many of the leading antibiotics were proving less effective in treating Covid. Someone quickly pointed out that ALL antibiotics are ineffective at treating Covid (a virus) since antibiotics ONLY treat bacterial infections, not viral infections. JPenis spent the next couple of days trying to backpedal and appear to not be this ignorant. If he's conversing with a real medical professional, at some point he will step in the dog shit once again and either delete the posts or backpedal when pointed out his knowledge on the topic is lacking.

All that being said, I believe Todos has hired the people with the requisite expertise to address the regulatory hurdles. One thing arpemd failed to mention is that Tollovir/Tollovid are botanical products, so the regulatory pathways are quite different than for the usual synthesized drugs. We know Todos is pursuing this approach since GC has spoken about it on numerous occasions. Neither JPenis or arpemd are discussing this approach, which raises doubts in my mind as to whether this discussion is designed to paint Todos in a bad light, and makes me question how much faith any investor should put on the accuracy of this discussion.